Emerging role of mTOR in the response to cancer therapeutics.
The movement toward precision medicine with targeted therapeutics for cancer treatment has been hindered by both innate and acquired resistance. Understanding the molecular wiring and plasticity of oncogenic signaling networks is essential to the development of therapeutic strategies to avoid or overcome resistance. The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) represents a highly integrated signaling node that is dysregulated in the majority of human cancers. Several studies have revealed that sustained mTORC1 inhibition is essential to avoid resistance to targeted therapeutics against the driving oncogenic pathway in a given cancer. Here we discuss the role of mTORC1 in dictating the response of tumors to targeted therapeutics and review recent examples from lung cancer, breast cancer, and melanoma.
Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, MA.
Erika
E
Ilagan
Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, MA.
Brendan D
BD
Manning
Nature. 2009 Dec 24;462(7276):1070-4
20033049
Trends Pharmacol Sci. 2015 Feb;36(2):124-35
25497227
Science. 1991 Aug 23;253(5022):905-9
1715094
Cancer Discov. 2013 Dec;3(12):1404-15
24065731
J Biol Chem. 2009 Mar 20;284(12):8023-32
19150980
Cell. 2014 Feb 13;156(4):771-85
24529379
Cell Metab. 2008 Sep;8(3):224-36
18762023
Cancer Discov. 2012 Mar;2(3):214-26
22585993
Clin Cancer Res. 2016 Jan 15;22(2):426-35
26341921
N Engl J Med. 2012 Jul 12;367 (2):107-14
22663011
Science. 2011 Jun 10;332(6035):1322-6
21659605
Trends Cell Biol. 2015 Sep;25(9):545-55
26159692
Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94
15342917
Cell Rep. 2014 May 22;7(4):999-1008
24813888
Cancer Cell. 2007 Jul;12(1):81-93
17613438
Mol Cell. 2006 Apr 21;22(2):159-68
16603397
Nature. 2002 Jun 27;417(6892):949-54
12068308
Nat Rev Clin Oncol. 2010 Sep;7(9):493-507
20551942
Science. 2013 Mar 15;339(6125):1320-3
23429704
Cancer Discov. 2015 Sep;5(9):960-71
26036643
Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17414-9
18955708
N Engl J Med. 2014 Oct 9;371(15):1426-33
25295501
Cancer Discov. 2014 May;4(5):546-53
24625776
Science. 2005 Feb 18;307(5712):1098-101
15718470
EMBO J. 2008 Jul 23;27(14):1919-31
18566587
Science. 2013 Jul 26;341(6144):1236566
23888043
Nat Rev Drug Discov. 2011 Oct 31;10(11):868-80
22037041
J Biol Chem. 2012 Mar 23;287(13):9742-52
22223645
Cancer Discov. 2014 Sep;4(9):1036-45
25074459
Science. 2013 May 31;340(6136):1100-6
23723238
Nat Rev Cancer. 2009 Aug;9(8):550-62
19629070
Cancer Res. 2016 Jan 15;76(2):227-38
26637667
Biochem J. 2008 Dec 15;416(3):375-85
18925875
Oncogene. 2008 Dec;27 Suppl 2:S43-51
19956179
Clin Cancer Res. 2013 Aug 15;19(16):4326-34
23770823
Cell. 2010 Apr 16;141(2):290-303
20381137
N Engl J Med. 2005 Feb 24;352(8):786-92
15728811
Cancer Discov. 2014 Sep;4(9):1046-61
24893891
Mol Cell. 2010 Jul 30;39(2):171-83
20670887
Nat Rev Cancer. 2014 Jul;14(7):455-67
24957944
Sci Signal. 2009 Apr 21;2(67):pe24
19383975
Nat Rev Cancer. 2007 Mar;7(3):169-81
17318210
Cancer Discov. 2011 Aug;1(3):248-59
22140653
Sci Transl Med. 2013 Jul 31;5(196):196ra99
23903756
Curr Biol. 2004 Sep 21;14(18):1650-6
15380067
Sci Signal. 2013 Sep 24;6(294):pe31
24065143
Trends Cell Biol. 2014 Jul;24(7):400-6
24698685
Sci Transl Med. 2013 Jul 31;5(196 ):196ra98
23903755
Cell. 2006 Feb 10;124(3):471-84
16469695
N Engl J Med. 2011 Jun 30;364(26):2507-16
21639808
Cell Rep. 2014 Jun 26;7(6):1824-32
24931608
N Engl J Med. 2008 Mar 13;358(11):1160-74
18337605
PLoS Med. 2005 Mar;2(3):e73
15737014
N Engl J Med. 2010 Nov 4;363(19):1801-11
21047224
Cell. 2007 Jun 29;129(7):1261-74
17604717
Nat Genet. 2016 Feb;48(2):183-8
26691987
Cell. 2012 Apr 13;149(2):274-93
22500797
Ann Neurol. 2006 Mar;59(3):490-8
16453317
Oncogene. 2016 Mar 10;35(10):1250-60
26028026
Lancet. 2012 Jul 28;380(9839):358-65
22735384
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6
12271141
Mol Cancer Ther. 2014 May;13(5):1117-29
24608574
Science. 2011 Jun 10;332(6035):1317-22
21659604
Nat Med. 2013 Nov;19(11):1389-400
24202392
Science. 2016 Feb 12;351(6274):728-33
26912861
Trends Immunol. 2015 Jan;36(1):13-20
25522665
Cell. 2005 Apr 22;121(2):179-93
15851026
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93
15731348
Nat Cell Biol. 2013 Jun;15(6):555-64
23728461
Cancer Discov. 2013 Mar;3(3):338-49
23171796
Nat Cell Biol. 2002 Sep;4(9):648-57
12172553
Science. 2012 Oct 12;338(6104):221
22923433
Cancer Discov. 2014 May;4(5):554-63
24631838
J Clin Invest. 2009 Oct;119(10 ):3000-10
19759520
Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70
15897464
EMBO J. 2008 Jul 23;27(14):1932-43
18566586
Mol Cell Biol. 2009 Nov;29(21):5657-70
19720745
Cancer Res. 2006 Feb 1;66(3):1500-8
16452206
Mol Cell. 2002 Jul;10 (1):151-62
12150915
J Cell Biol. 2004 Nov 8;167(3):399-403
15533996
Sci Signal. 2013 Sep 24;6(294):re6
24065147
Cell Metab. 2014 Mar 4;19(3):373-9
24508508
Oncogene. 2008 Sep 18;27(41):5497-510
18794884
PLoS Biol. 2009 Feb 10;7(2):e38
19209957
Science. 2013 Mar 15;339(6125):1323-8
23429703
Biochem Soc Trans. 2013 Aug;41(4):906-12
23863154
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21124-9
24327733
N Engl J Med. 2008 Jan 10;358(2):140-51
18184959
Cancer Cell. 2015 Apr 13;27(4):533-46
25873175
J Cell Biol. 2004 Jul 19;166(2):213-23
15249583